<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cenexis Bio - Confidential Briefing</title>
    <meta name="description" content="Cenexis Bio: Industrializing the LLNL-02 nerve agent antidote for national security stockpiles.">
    <link rel="stylesheet" href="style.css">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700;800&display=swap" rel="stylesheet">
</head>
<body>

    <header>
        <div class="brand">CENEXIS BIO</div>
        <nav>
            <a href="#gap">The Gap</a>
            <a href="#solution">Solution</a>
            <a href="#status">Status</a>
            <a href="#team">Team</a>
            <a href="#contact" style="color: var(--brand-red);">Request Access</a>
        </nav>
    </header>

    <main>
        <section class="hero">
            <span class="eyebrow">CONFIDENTIAL BRIEFING // [LLNL-02 / CX-101]</span>
            <h1>Beyond Survival.<br><span style="opacity: 0.4;">Protecting the Cognitive Edge.</span></h1>
            <p class="hero-subtitle">Cenexis Bio is developing the next generation of nerve agent antidotes. We are the execution bridge designed to preserve both life and brain function for U.S. and Allied stockpiles.</p>
            <a href="#gap" class="cta-arrow">VIEW THE MISSION ↓</a>
        </section>

        <section id="gap">
            <span class="eyebrow">Strategic Analysis</span>
            <h2>The Status Quo is Grossly Inadequate</h2>
            <div class="content-block">
                <p>Nerve agents—including Sarin, VX, and Novichok—remain a credible and evolving threat in asymmetric conflicts. Current medical countermeasures (legacy oximes) save lives; however, they were designed for survival, not neuroprotection.</p>
                <ul>
                    <li><strong>The Barrier:</strong> Existing legacy antidotes possess limited CNS penetration.</li>
                    <li><strong>The Consequence:</strong> Survivors often suffer rapid, irreversible neurologic damage due to central seizure activity.</li>
                    <li><strong>The Gap:</strong> There are currently no FDA-approved CNS-protective antidotes in the Strategic National Stockpile.</li>
                </ul>
                <blockquote style="border-left: 2px solid var(--brand-red); padding: 10px 0 10px 25px; font-style: italic; color: var(--white); margin: 30px 0; font-size: 18px;">
                    "Current countermeasures keep the victim alive but leave them unprotected from long-term neurologic injury."
                </blockquote>
            </div>
        </section>

        <section class="comparison-grid" id="solution">
            <div class="status-block">
                <h4 style="color: var(--brand-red); font-family: var(--font-mono); font-size: 11px; text-transform: uppercase;">BLOOD-BRAIN BARRIER: BLOCKED</h4>
                <p style="color: var(--text-main);">Legacy oxime solutions fail to reach the brain effectively, leaving central nervous system targets vulnerable to irreversible damage.</p>
            </div>
            <div class="status-block" style="border-left: 1px solid #333; padding-left: 40px;">
                <h4 style="color: #2cc55e; font-family: var(--font-mono); font-size: 11px; text-transform: uppercase;">TARGET: PENETRATED</h4>
                <h3 style="color: #2cc55e; margin-bottom: 10px;">LLNL-02 / CX-101</h3>
                <p style="color: var(--text-main);">The first nerve-agent antidote engineered to cross the blood-brain barrier and preserve high-level cognitive function.</p>
            </div>
        </section>

        <section>
            <span class="eyebrow">Therapeutic Profile</span>
            <h2>True CNS Defense: LLNL-02 / CX-101</h2>
            <p>Developed at Lawrence Livermore National Laboratory (LLNL), LLNL-02 / CX-101 is engineered to replace the 60-year-old agents currently in the Strategic National Stockpile.</p>
            
            <div class="team-grid" style="margin-top: 40px;"> 
                <div class="team-member">
                    <h3>First-in-Class CNS Penetration</h3>
                    <p>Designed by LLNL research scientists as a novel therapeutic capable of crossing the blood-brain barrier to stop seizures.</p>
                </div>
                <div class="team-member">
                    <h3>5x Longer Exposure</h3>
                    <p>Pharmacokinetic data demonstrates approximately 5x longer durable systemic exposure than standard-of-care legacy antidotes.</p>
                </div>
                <div class="team-member">
                    <h3>Drop-In Readiness</h3>
                    <p>Engineered as a superior replacement for legacy oximes, fully compatible with existing autoinjector platforms for rapid deployment.</p>
                </div>
            </div>
        </section>

        <section id="status">
            <span class="eyebrow">Execution Readiness</span>
            <h2>De-Risked Execution</h2>
            <p>Cenexis Bio operates a mandated execution program aligned with U.S. national security requirements.</p>
            <div class="stats-grid">
                <div class="stat-item">
                    <h3>$7M</h3>
                    <p>Gov Investment</p>
                </div>
                <div class="stat-item">
                    <h3>LLNL</h3>
                    <p>Research Origin</p>
                </div>
                <div class="stat-item">
                    <h3>FDA</h3>
                    <p>Animal Rule</p>
                </div>
                <div class="stat-item">
                    <h3>USG</h3>
                    <p>Validated Buyer</p>
                </div>
            </div>
        </section>

        <section id="team">
            <span class="eyebrow">Project Governance</span>
            <h2>The Architects</h2>
            <div class="team-grid">
                <div class="team-member">
                    <span class="team-role">Chief Executive Officer</span>
                    <h3>Ray Stevens, MBA</h3>
                    <p>Decades of experience in program execution and high-stakes biopharmaceutical leadership.</p>
                </div>
                <div class="team-member">
                    <span class="team-role">Chief Medical Officer</span>
                    <h3>Stewart McCallum, MD FACS</h3>
                    <p>20+ years of global development and regulatory expertise.</p>
                </div>
                <div class="team-member">
                    <span class="team-role">Head, CMC & Quality</span>
                    <h3>Dale Bennyhoff</h3>
                    <p>25+ years in CMC, industrial scale-up, and GMP readiness for advanced therapeutics.</p>
                </div>
                <div class="team-member">
                    <span class="team-role">CBO / CFO</span>
                    <h3>Bryan Katz, MBA</h3>
                    <p>26-year pharma leader and U.S. Marine, focusing on the intersection of commerce and national defense.</p>
                </div>
            </div>
        </section>
    </main>

    <footer class="footer" id="contact">
            <h2>Restricted Access</h2>
            <p style="margin: 0 auto 30px auto; max-width: 600px;">Cenexis Bio is currently executing a government-aligned Series A roadmap. Detailed data rooms and briefing materials are available only to authorized parties.</p>
        </div>
        
        <div style="text-align: center; margin-top: 40px;">
            <div class="contact-links">
                <a href="mailto:info@cenexisbio.com">Ray Stevens (CEO) – info@cenexisbio.com</a>
                <a href="mailto:info@cenexisbio.com">Bryan Katz (CBO) – info@cenexisbio.com</a>
            </div>
            <p style="margin-top: 60px; font-size: 10px; font-family: var(--font-mono); opacity: 0.3;">© 2026 CENEXIS BIO. PROPERTY OF CENEXIS BIO. WEST CHESTER, PA. UNAUTHORIZED DISTRIBUTION PROHIBITED.</p>
        </div>
    </footer>

</body>
</html>
